Free tool
Drug Trial Radar: Endocrinology and women's health
Last checked: Nov 20, 2026Latest source record: Oct 14, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
188
Completed, industry sponsors, Endocrinology and women's health, Phase 2
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed188
188 trials
Showing 1 to 25, recently updated first.
Crinetics Pharmaceuticals Inc.Industry
NCT05804669 · 19 participants · Start Oct 12, 2023 · Primary completion Aug 25, 2026
Drug: atumelnant · For: Cushing Syndrome; Cushing Disease; Ectopic ACTH Syndrome
Sites: Bethesda, Maryland
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Industry
NCT07814651 · 78 participants · Start Apr 16, 2024 · Primary completion Apr 9, 2026
Drug: SYHX2008; Sandostatin LAR · For: Acromegaly
Sites: Shanghai, China
- A Study to Learn About the Study Medicine PF-07220060 Together With Letrozole Compared to Letrozole Alone in Women Post MenopausePivotal-lookingCompleted
PfizerPfizer (PFE)
NCT06465368 · 121 participants · Start Jul 11, 2024 · Primary completion Jul 10, 2025
Drug: PF-07220060; letrozole · For: Breast Cancer
Sites: Barrington, Illinois; Crystal Lake, Illinois; Park Ridge, Illinois · 51 sites in all
Ascendis Pharma A/SIndustry
NCT01247675 · 37 participants · Start Nov 2010 · Primary completion May 2011
Drug: ACP-001 (TransCon hGH); ACP-001 (TransCon hGH) and 2 more · For: Adult Growth Hormone Deficiency
Sites: Aarhus, Denmark; Berlin, Germany; Genova, Italy · 4 sites in all
Ascendis Pharma A/SIndustry
NCT01947907 · 53 participants · Start Jul 2013 · Primary completion Jul 2015
Drug: ACP-001; Human Growth Hormone · For: Growth Hormone Deficiency (GHD)
Sites: Minsk, Belarus; Varna, Bulgaria; Ústí nad Labem, Czechia · 36 sites in all
- Phase 2 Study of LUM-201 in Children With Growth Hormone Deficiency (OraGrowtH210 Trial)Pivotal-lookingCompleted
Lumos PharmaIndustry
NCT04614337 · 104 participants · Start Dec 31, 2020 · Primary completion Sep 4, 2024
Drug: LUM-201; rhGH Norditropin® pen (34 µg/kg) · For: Growth Hormone Deficiency
Sites: Sacramento, California; San Diego, California; Greenwood Village, Colorado · 43 sites in all
Lumos PharmaIndustry
NCT05250063 · 15 participants · Start Feb 18, 2022 · Primary completion Jan 22, 2025
Drug: LUM-201 · For: Growth Hormone Deficiency
Sites: San Diego, California; Washington D.C., District of Columbia; Indianapolis, Indiana · 10 sites in all
- A Study to Investigate Efficacy and Safety of OG-6219 BID in 3 Dose Levels Compared With Placebo in Participants Aged 18 to 49 With Moderate to Severe Endometriosis-related PainPivotal-lookingCompleted
Organon and CoIndustry
NCT05560646 · 354 participants · Start Oct 25, 2022 · Primary completion May 28, 2025
Drug: OG-6219; Placebo · For: Endometriosis
Sites: Birmingham, Alabama; Los Angeles, California; Orange, Connecticut · 86 sites in all
- A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Chinese Women Going Through MenopausePivotal-lookingCompleted
Astellas Pharma Global Development, Inc.Astellas (ALPMY)
NCT06812754 · 150 participants · Start Mar 10, 2025 · Primary completion Feb 11, 2026
Drug: Fezolinetant; Placebo · For: Hot Flashes
Sites: Beijing, China; Guangzhou, China; Shenzhen, China · 26 sites in all
- A Study Evaluation the Safety and Efficacy of Hormone Replacement Therapy With North Star Compared to Levothyroxine in Patients With Primary HypothyroidismPivotal-lookingCompleted
Neuvosyn Laboratories, LLCIndustry
NCT05712421 · 303 participants · Start Feb 28, 2023 · Primary completion May 5, 2025
Drug: North Star; Levothyroxine · For: Hypothyroidism
Sites: Birmingham, Alabama; Canoga Park, California; Greenbrae, California · 31 sites in all
Sparrow PharmaceuticalsIndustry
NCT05436639 · 30 participants · Start Jul 1, 2023 · Primary completion Dec 1, 2024
Drug: SPI-62 dose · For: Autonomous Cortisol Secretion (ACS); ACTH-Independent Cushing Syndrome; ACTH-Independent Adrenal Cushing Syndrome, Somatic
Sites: Rochester, Minnesota; Columbus, Ohio; Brasov, Romania · 5 sites in all
- MT-8554 for Reduction of Vasomotor Symptoms in Postmenopausal WomenPivotal-lookingCompleted
Tanabe Pharma America, Inc.Industry
NCT03291067 · 375 participants · Start Oct 9, 2017 · Primary completion Oct 19, 2018
Drug: MT-8554 1mg; MT-8554 5mg and 2 more · For: Menopause Hot Flashes
Sites: Birmingham, Alabama; Dothan, Alabama; Phoenix, Arizona · 63 sites in all
- A Study to Assess the Efficacy and Safety of HMI-115 in Subjects With Endometriosis-Associated PainPivotal-lookingCompleted
Hope Medicine (Nanjing) Co., LtdIndustry
NCT05101317 · 142 participants · Start Oct 11, 2021 · Primary completion Sep 26, 2024
Drug: HMI-115; Placebo · For: Endometriosis
Sites: Draper, Utah; Norfolk, Virginia; Beijing, China · 5 sites in all
Novo Nordisk A/SNovo Nordisk (NVO)
NCT02616562 · 76 participants · Start Mar 31, 2016 · Primary completion Sep 26, 2024
Drug: somapacitan; Norditropin® FlexPro® pen · For: Growth Hormone Disorder; Growth Hormone Deficiency in Children
Sites: Birmingham, Alabama; Los Angeles, California; Madera, California · 89 sites in all
Novartis PharmaceuticalsNovartis (NVS)
NCT03056755 · 383 participants · Start Aug 29, 2017 · Primary completion Jun 14, 2021
Drug: Alpelisib; Fulvestrant and 3 more · For: Breast Cancer
Sites: Gilbert, Arizona; Phoenix, Arizona; Anaheim, California · 94 sites in all
Tanabe Pharma America, Inc.Industry
NCT03840993 · 76 participants · Start Jan 15, 2019 · Primary completion May 13, 2021
Drug: MT-2990; Placebo · For: Endometrial Related Pain
Sites: Phoenix, Arizona; Sacramento, California; San Diego, California · 51 sites in all
- A Study to Learn About How Elinzanetant Works and How Safe it is in Women Having Sleep Disturbances Associated With MenopausePivotal-lookingCompleted
BayerBayer (BAYRY)
NCT06112756 · 110 participants · Start Nov 8, 2023 · Primary completion Aug 22, 2024
Drug: Elinzanetant · For: Sleep Disturbances Associated With Menopause
Sites: Little Port Walter, Alaska; Scottsdale, Arizona; Encinitas, California · 40 sites in all
Sparrow PharmaceuticalsIndustry
NCT05307328 · 26 participants · Start Sep 1, 2022 · Primary completion Aug 1, 2025
Drug: SPI-62; Placebo · For: Cushing's Syndrome I; Cushing Disease Due to Increased ACTH Secretion; Cortisol Excess and 3 more
Sites: Phoenix, Arizona; Fort Myers, Florida; Rochester, Minnesota · 12 sites in all
Noema Pharma AGIndustry
NCT06385795 · 40 participants · Start Apr 22, 2024 · Primary completion Aug 13, 2025
Drug: NOE-115 · For: Menopause Syndrome; Menopause; Hot Flashes
Sites: San Diego, California; Jacksonville, Florida; Atlanta, Georgia · 5 sites in all
- A Trial Using ARV-471 or Anastrozole in Post-Menopausal Women With Breast Cancer Prior to SurgeryPivotal-lookingCompleted
Arvinas Inc.Industry
NCT05549505 · 152 participants · Start Feb 15, 2023 · Primary completion Jul 13, 2024
Drug: ARV-471; Anastrozole · For: Breast Cancer
Sites: Springdale, Arkansas; Los Angeles, California; Torrance, California · 49 sites in all
Xeris PharmaceuticalsIndustry
NCT05823012 · 46 participants · Start May 15, 2023 · Primary completion Feb 22, 2024
Drug: levothyroxine sodium · For: Hypothyroidism
Sites: Chula Vista, California; Montclair, California; Miami Lakes, Florida · 6 sites in all
- Long Term Follow up Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient ChildrenCompleted
OPKO Health, Inc.Industry
NCT02500316 · 48 participants · Start Feb 2014 · Primary completion Nov 2023
Drug: MOD-4023 · For: Growth Hormone Deficiency (GHD)
Sites: Jacksonville, Florida; Minsk, Belarus; Athens, Greece · 13 sites in all
Crinetics Pharmaceuticals Inc.Industry
NCT03792555 · 13 participants · Start Mar 11, 2019 · Primary completion Jul 15, 2020
Drug: Paltusotine; Placebo · For: Acromegaly
Sites: Columbus, Ohio; Dallas, Texas; Curitiba, Brazil · 11 sites in all
Crinetics Pharmaceuticals Inc.Industry
NCT03789656 · 47 participants · Start Mar 12, 2019 · Primary completion Aug 3, 2020
Drug: Paltusotine · For: Acromegaly
Sites: Los Angeles, California; Chicago, Illinois; Boston, Massachusetts · 26 sites in all
BayerBayer (BAYRY)
NCT02865538 · 76 participants · Start Aug 1, 2016 · Primary completion Mar 28, 2017
Drug: BAY3427080; Placebo (for BAY3427080) · For: Post-menopausal Vasomotor Symptoms
Sites: DeLand, Florida; Miami, Florida; San Antonio, Texas
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.